Apton Biosystems develops a sequencing-based molecular profiling platform with a high-throughput system for human genome sequencing that also analyzes proteins and nucleic acids. The system enables biomarker discovery, early disease detection, and therapeutic monitoring using single-molecule detection technology for individual cancer biomarkers. Founded in 2012 in Pleasanton, United States, the company has raised $34.5M in Series A funding from investors including Khosla Ventures, Samsung Catalyst Fund, and Casdin Capital. Developer of a sequencing-based molecular profiling platform. The platform is developing a high throughput system for the human genome sequence. The system can also analyze several proteins and nucleic acids. Also, it allows biomarker discovery, early disease detection, and therapeutic monitoring.
Apton Biosystems
Series AApton Biosystems develops a sequencing-based molecular profiling platform with a high-throughput system for human genome sequencing that also analyzes proteins and nucleic acids. The system enables biomarker discovery, early disease detection, and therapeutic monitoring using single-molecule detection technology for individual cancer biomarkers. Founded in 2012 in Pleasanton, United States, the company has raised…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine
Team background
College Wise > University of California (Berkeley), Stanford University
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.